Yukihito Ishizaka Selected Research

Yukihito Ishizaka Research Topics

Disease

14	Infections 10/2023 - 01/2006
10	Neoplasms (Cancer) 01/2024 - 06/2005
9	COVID-19 11/2023 - 06/2021
3	Disease Progression 11/2023 - 01/2021
3	Respiratory Insufficiency (Respiratory Failure) 11/2022 - 06/2008
3	COVID-19 reinfection 11/2022 - 07/2021
3	Fibrosis (Cirrhosis) 01/2020 - 05/2014
2	Reinfection 11/2022 - 07/2021
2	Genomic Instability 11/2022 - 03/2016
2	Persistent Infection 07/2022 - 04/2022
2	Fever (Fevers) 07/2022 - 01/2021
2	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2018 - 02/2013
2	Acquired Immunodeficiency Syndrome (AIDS) 01/2013 - 06/2010
2	Virus Diseases (Viral Diseases) 06/2011 - 06/2008
1	Asthma (Bronchial Asthma) 11/2023
1	Liver Failure 01/2023
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 07/2022
1	Breakthrough Infections 07/2022
1	Post-Acute COVID-19 Syndrome 04/2022
1	Pleural Tuberculosis 03/2022
1	Pneumonia (Pneumonitis) 07/2021
1	Diabetes Mellitus 06/2021
1	COVID-19 related pediatric multisystem inflammatory disease 01/2021
1	Myocarditis (Carditis) 01/2021
1	Inflammation (Inflammations) 01/2019
1	Mental Disorders (Mental Disorder) 07/2016
1	Neurocognitive Disorders (Clerambault Syndrome) 07/2015
1	Bites and Stings (Sting) 07/2015
1	Pulmonary Hypertension 02/2015

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 06/2022 - 06/2008
6	Immunoglobulin G (IgG)IBA 01/2024 - 06/2021
5	AntibodiesIBA 11/2023 - 06/2021
4	vpr Gene ProductsIBA 01/2024 - 01/2013
4	VaccinesIBA 10/2023 - 01/2022
4	Liposomes (Liposome)IBA 12/2015 - 09/2010
3	EnzymesIBA 01/2024 - 06/2008
3	Neutralizing AntibodiesIBA 11/2022 - 07/2021
3	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 01/2006
3	PolymersIBA 12/2015 - 09/2010
2	ImmunosorbentsIBA 01/2024 - 06/2021
2	ElementsIBA 04/2022 - 06/2005
2	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2018 - 06/2011
2	NucleotidesIBA 01/2015 - 11/2011
2	AutoantibodiesIBA 07/2014 - 01/2010
2	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2010 - 04/2003
1	Interleukin-6 (Interleukin 6)IBA 01/2024
1	Detergents (Detergent)IBA 01/2024
1	Immunoglobulins (Immunoglobulin)IBA 01/2024
1	ciclesonide FDA Link 11/2023
1	SteroidsIBA 11/2023
1	Human Serum Albumin FDA LinkGeneric 01/2023
1	ResveratrolIBA 11/2022
1	Rituximab (Mabthera)FDA Link 07/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 07/2022
1	2019-nCoV Vaccine mRNA-1273IBA 06/2022
1	Viral ProteinsIBA 04/2022
1	Adenosine DeaminaseIBA 03/2022
1	casirivimab and imdevimab drug combinationIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	Oxygen (Dioxygen)IBA 07/2021
1	C-Reactive ProteinIBA 06/2021
1	DiureticsIBA 01/2021
1	CytokinesIBA 01/2021
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021
1	Prednisolone (Predate)FDA LinkGeneric 01/2021
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2021
1	Vasodilator Agents (Vasodilators)IBA 01/2021
1	Reverse Transcriptase InhibitorsIBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	GalactosidasesIBA 01/2020
1	ChemokinesIBA 01/2019
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 01/2019
1	LigandsIBA 01/2019
1	Collagen Type IV (Type IV Collagen)IBA 07/2018
1	Thioacetamide (Thioacetamid)IBA 07/2018
1	Therapeutic UsesIBA 07/2018
1	Glutamate Receptors (Glutamate Receptor)IBA 07/2016
1	Morphine (MS Contin)FDA LinkGeneric 03/2016
1	Fentanyl (Sublimaze)FDA LinkGeneric 03/2016
1	Drug CarriersIBA 12/2015
1	InterferonsIBA 07/2015
1	GlutaminaseIBA 07/2015
1	Deoxyribonuclease I (Nickase)IBA 07/2015
1	Glutamic Acid (Glutamate)FDA Link 07/2015
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 07/2015
1	Caveolin 1IBA 02/2015
1	MonocrotalineIBA 02/2015
1	Drinking WaterIBA 01/2015
1	CarcinogensIBA 01/2015
1	Dextrans (Dextran)FDA Link 01/2015
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2015
1	AzoxymethaneIBA 01/2015

Therapy/Procedure

7	Therapeutics 01/2024 - 06/2010
4	Drug Therapy (Chemotherapy) 02/2014 - 06/2005
2	Precision Medicine 12/2015 - 01/2015
1	Critical Care (Surgical Intensive Care) 11/2022
1	Renal Dialysis (Hemodialysis) 11/2022
1	Cannula 07/2021
1	Highly Active Antiretroviral Therapy (HAART) 01/2020
1	Aftercare (After-Treatment) 01/2015